Genetesis Inc.
13
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.7%
1 terminated/withdrawn out of 13 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
Role: lead
A Registry of Cardiac PET and CardioFlux Magnetocardiography in Patients With Suspected Coronary Ischemia.
Role: lead
MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR
Role: lead
Magnetocardiography Endocrine Registry
Role: lead
MCG as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction
Role: lead
Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy
Role: lead
Acute Coronary Syndrome CardioFlux TM Study (ACCMED)
Role: lead
Mason Heart Study With MCG
Role: lead
Women's Assessed Cardiovascular Evaluation With MCG
Role: lead
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Role: lead
Genetesis Accelerated Registry
Role: lead
Magnetocardiography Using a Novel Analysis System (Cardioflux) in the Evaluation of Emergency Department Observation Unit Chest Pain Patients
Role: lead
Use of Magnetocardiography in Evaluation of Patients Going for Cardiac Catheterization
Role: lead
All 13 trials loaded